Jameson Legal

 

Resource

 

 

 

 

 

 

 

 

 

 

 

Financing of Axovant

23 Feb 2017

Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, entered into a $55.0 million debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), a leader in customized debt financing for companies in life sciences and technology-related markets.

VISCHER advises Axovant in this financing in Swiss law matters, the team consists of Dr. Adrian Dörig (Partner, Corporate), Christoph Niederer (Partner, Tax), Dania Salvisberg (Senior Associate, Corporate) and Ruben Masar (Associate, Corporate).

Matter Type
Banking & Finance - Capital Markets: Debt
Industry
Healthcare, Life Sciences & Chemicals
News Category
Banking & Finance